Navigation Links
Misonix Announces Completion of Product Registrations in Key Latin American Markets
Date:2/7/2011

FARMINGDALE, N.Y., Feb. 7, 2011 /PRNewswire/ -- Misonix, Inc. (Nasdaq: MSON), a medical device company that designs, manufactures, and markets innovative, therapeutic, ultrasonic products worldwide for wound debridement, cosmetic surgery, neurosurgery, laparoscopic surgery, and other surgical and medical applications, announced the completion of product registrations in Argentina, Brazil, Colombia and Peru.  Open market sales via exclusive distributors have commenced in these Latin American countries.

In Argentina, the BoneScalpel™ Ultrasonic Bone Cutting System and the SonaStar® Ultrasonic Surgical Aspiration System are now registered.  Registration is complete in Brazil for the SonaStar and is in process for BoneScalpel.  In Colombia and Peru, BoneScalpel, SonaStar and the SonicOne® Ultrasonic Wound Debridement System have completed the registration process.

The SonaStar is used for quick and efficient removal of both hard and soft tumors while sparing most vessels.  In addition, OsteoSculpt™ bone sculpting technology can be employed with the SonaStar to safely remove osseous structures, thus providing access to the surgical site.

The BoneScalpel is a tissue specific osteotomy device capable of making precise cuts through bone and hard tissue while largely preserving delicate soft tissue structures.  It offers the convenience and speed of a power instrument without the danger associated with rotary sharps.

The SonicOne is an innovative, ultrasonic wound care system that offers tissue specific debridement and cleansing for effective removal of devitalized tissue and fibrin deposits while sparing viable cellular structures.  The SonicOne establishes a new standard in advanced wound care and ensures progress towards patient healing.

"Misonix is pleased by the outcomes of the lengthy registration process required by the health ministries in many Latin American countries.  Latin America is a geographic market segment that Misonix has targeted for near-term sales growth with particular emphasis in Brazil," said Michael A. McManus, Jr., President and Chief Executive Officer of Misonix.

About Misonix:Misonix, Inc. designs, develops, manufactures and markets therapeutic ultrasonic medical devices and laboratory equipment.  Misonix's therapeutic ultrasonic platform is the basis for several innovative medical technologies.  Addressing a combined market estimated to be in excess of $3 billion annually; Misonix's proprietary ultrasonic medical devices are used for wound debridement, cosmetic surgery, neurosurgery, laparoscopic surgery, and other surgical and medical applications.  Additional information is available on the Company's Web site at www.misonix.com.

With the exception of historical information contained in this press release, content herein may contain "forward looking statements" that are made pursuant to the Safe Harbor Provisions of the Private Securities Litigation Reform Act of 1995.  These statements are based on management's current expectations and are subject to uncertainty and changes in circumstances.  Investors are cautioned that forward-looking statements involve risks and uncertainties that could cause actual results to differ materially from the statements made. These factors include general economic conditions, delays and risks associated with the performance of contracts, risks associated with international sales and currency fluctuations, uncertainties as a result of research and development, acceptable results from clinical studies, including publication of results and patient/procedure data with varying levels of statistical relevancy, risks involved in introducing and marketing new products, potential acquisitions, consumer and industry acceptance, litigation and/or court proceedings, including the timing and monetary requirements of such activities, the timing of finding strategic partners and implementing such relationships,  regulatory risks including approval of pending and/or contemplated 510(k) filings, the ability to achieve and maintain profitability in the Company's business lines, and other factors discussed in the Company's Annual Report on Form 10-K, subsequent Quarterly Reports on Form 10-Q and Current Reports on Form 8-K.  The Company disclaims any obligation to update its forward-looking relationships.Investor Relations Contact:Kevin McGrath/Cameron Associates, Inc.212-245-4577Kevin@cameronassoc.com
'/>"/>

SOURCE Misonix, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Misonix Schedules Fourth Quarter and Fiscal Year 2009 Financial Results Conference Call; October 1, 2009 at 4:30 p.m. Eastern
2. Misonix Reports Fourth Quarter and Fiscal Year 2009 Financial Results
3. Misonix, Inc. Announces the Sale of Sonora Medical Systems for $8 Million
4. Misonix Announces New Distribution Agreement for United Kingdom and Republic of Ireland
5. Misonix Announces New Distribution Agreement for Mexico
6. Misonix Schedules First Quarter 2010 Financial Results Conference Call; November 16, 2009 at 4:30 p.m. Eastern
7. Misonix Announces New Distribution Agreement for Saudi Arabia and Other Middle Eastern Countries
8. Misonix Announces New Distribution Agreement for Peru
9. Misonix Announces New Distribution Agreement For The United Arab Emirates (UAE)
10. Misonix Announces New Distribution Agreement for Argentina
11. Misonix Announces New Distribution Agreement for Kingdom of Saudi Arabia
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/4/2016)... -- Summary Breast cancer, a malignant neoplasm, is ... cancer in women worldwide, accounting for 16% of all ... of women diagnosed with breast cancer has increased over ... has declined due to earlier diagnosis and better treatment ... the past four decades, especially with increasing usage of ...
(Date:2/4/2016)... MOUNTAIN VIEW, Calif., Feb. 4, 2016  Omnicell, Inc. (NASDAQ: ... supply management solutions to healthcare systems, today announced results ... 2015.  --> --> ... was $130.3 million, up $5.1 million or 4.1% from ... or 7.2% from the fourth quarter of 2014. Revenue ...
(Date:2/4/2016)... , Feb. 4, 2016 In response to the ... FDA,s Deputy Commissioner for Medical Products and Tobacco, along with ... reassess the agency,s approach to opioid medications. The plan will ... providing patients in pain access to effective relief. ... , Re-examine the risk-benefit paradigm for opioids and ...
Breaking Medicine Technology:
(Date:2/5/2016)... ... February 05, 2016 , ... Love is in the air at ... of colors, assortments and packaging. This staple for Valentine’s Day is a must-have, and ... , For Valentine’s Day, not only are long-stem roses available, but also other flower ...
(Date:2/5/2016)... ... February 05, 2016 , ... The Muscular Dystrophy Association and ... launched the 14th annual “Appetite for a Cure” campaign on Feb. 1 to ... and related diseases that severely limit strength and mobility. , Now through ...
(Date:2/5/2016)... ... February 05, 2016 , ... The ... funding innovative lymphoma research and serving the lymphoma community through a comprehensive series ... again host, Swirl, A Wine Tasting Event at the La Gorce Country Club ...
(Date:2/5/2016)... Dallas, Texas (PRWEB) , ... February 05, 2016 , ... ... to allow users to search for and donate to Give To Cure’s campaign ... is an app that lets users make and share payments through a smart device. ...
(Date:2/5/2016)... MA (PRWEB) , ... February 05, 2016 , ... ... in tattoo technology, the PicoSure. Designed to provide the most effective tattoo removal today, ... option with unmatched results. , Developed by Cynosure, the PicoSure has been approved by ...
Breaking Medicine News(10 mins):